|
|
News Breaks | | | | January 3, 2013 | | 09:02 EDT |  | AEZS | Aeterna Zentaris upgraded to Buy from Hold at MLV Equity
MLV Equity believes Aeterna Zentaris' pipeline drugs, AEZS-108 and AEZS-130, have substantial value and that DSMB recommendation on Perifosine in Q1 could act as a catalysts. Price target is $5.50. | |
|
News For AEZS From The Last 14 Days Check below for free stories on AEZS the last two weeks. |
|
|
| May 7, 2013 | | 16:48 EDT |  | AEZS | Aeterna Zentaris reports Q1 EPS 7c vs. (65c) a year ago
Reports Q1 revenue $16.6M vs. $9.5M a year ago. | |
|
|
|
|
|
|
